Alkermes plc

NasdaqGS:ALKS Stock Report

Market Cap: US$5.0b

Alkermes Valuation

Is ALKS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALKS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$59.98
Fair Value
49.8% undervalued intrinsic discount
14
Number of Analysts

Below Fair Value: ALKS ($30.13) is trading below our estimate of fair value ($59.98)

Significantly Below Fair Value: ALKS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALKS?

Key metric: As ALKS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALKS. This is calculated by dividing ALKS's market cap by their current earnings.
What is ALKS's PE Ratio?
PE Ratio14x
EarningsUS$355.65m
Market CapUS$5.01b

Price to Earnings Ratio vs Peers

How does ALKS's PE Ratio compare to its peers?

The above table shows the PE ratio for ALKS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.9x
HALO Halozyme Therapeutics
16.7x14.8%US$8.3b
EXEL Exelixis
19.1x22.5%US$10.1b
BMRN BioMarin Pharmaceutical
21.5x18.6%US$11.5b
VCYT Veracyte
70.1x28.3%US$2.4b
ALKS Alkermes
14x-10.5%US$5.0b

Price-To-Earnings vs Peers: ALKS is good value based on its Price-To-Earnings Ratio (14x) compared to the peer average (31.9x).

Price to Earnings Ratio vs Industry

How does ALKS's PE Ratio compare vs other companies in the US Biotechs Industry?

14 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AGIO Agios Pharmaceuticals
2.4x-23.1%US$1.62b
NVAX Novavax
2x-51.1%US$967.77m
INBX Inhibrx Biosciences
0.1xn/aUS$163.00m
PBYI Puma Biotechnology
3.8x-41.2%US$152.37m
ALKS 14.0xIndustry Avg. 16.7xNo. of Companies14PE01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALKS is good value based on its Price-To-Earnings Ratio (14x) compared to the US Biotechs industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is ALKS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALKS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14x
Fair PE Ratio12.6x

Price-To-Earnings vs Fair Ratio: ALKS is expensive based on its Price-To-Earnings Ratio (14x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALKS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$30.13
US$39.57
+31.3%
13.7%US$52.00US$30.00n/a14
May ’26US$30.58
US$39.36
+28.7%
13.8%US$52.00US$30.00n/a14
Apr ’26US$32.53
US$39.20
+20.5%
13.6%US$52.00US$30.00n/a15
Mar ’26US$34.33
US$36.43
+6.1%
18.6%US$46.00US$21.00n/a14
Feb ’26US$31.53
US$34.23
+8.6%
17.7%US$43.00US$21.00n/a13
Jan ’26US$28.76
US$34.08
+18.5%
18.2%US$43.00US$21.00n/a13
Dec ’25US$29.02
US$34.08
+17.4%
18.2%US$43.00US$21.00n/a13
Nov ’25US$26.47
US$32.62
+23.2%
19.8%US$43.00US$21.00n/a13
Oct ’25US$28.83
US$34.69
+20.3%
22.1%US$50.00US$21.00n/a13
Sep ’25US$28.45
US$34.69
+21.9%
22.1%US$50.00US$21.00n/a13
Aug ’25US$26.86
US$34.69
+29.2%
22.1%US$50.00US$21.00n/a13
Jul ’25US$24.39
US$34.62
+41.9%
21.8%US$50.00US$21.00n/a13
Jun ’25US$23.40
US$34.67
+48.1%
22.6%US$50.00US$21.00n/a12
May ’25US$24.01
US$34.50
+43.7%
20.0%US$50.00US$23.00US$30.5812
Apr ’25US$27.24
US$34.83
+27.9%
13.8%US$43.00US$25.00US$32.5312
Mar ’25US$30.24
US$34.64
+14.5%
14.3%US$43.00US$25.00US$34.3311
Feb ’25US$26.94
US$33.09
+22.8%
12.6%US$42.00US$25.00US$31.5311
Jan ’25US$27.74
US$33.09
+19.3%
13.9%US$42.00US$25.00US$28.7611
Dec ’24US$24.29
US$33.09
+36.2%
13.9%US$42.00US$25.00US$29.0211
Nov ’24US$24.54
US$33.10
+34.9%
14.6%US$42.00US$25.00US$26.4710
Oct ’24US$28.01
US$36.67
+30.9%
15.0%US$49.00US$30.00US$28.839
Sep ’24US$29.27
US$36.67
+25.3%
15.0%US$49.00US$30.00US$28.459
Aug ’24US$28.54
US$36.67
+28.5%
14.0%US$48.00US$30.00US$26.869
Jul ’24US$31.30
US$36.22
+15.7%
13.9%US$48.00US$30.00US$24.399
Jun ’24US$29.28
US$35.10
+19.9%
13.6%US$48.00US$30.00US$23.4010
May ’24US$28.64
US$34.80
+21.5%
14.3%US$48.00US$30.00US$24.0110
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
US$39.57
Fair Value
23.9% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/09 16:18
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alkermes plc is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Robert HazlettBMO Capital Markets U.S. (Historical)
Jason Matthew GerberryBofA Global Research